ANIX (Anixa Biosciences) ROE % Adjusted to Book Value: -9.69% (As of Apr. 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.57
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences ROE % Adjusted to Book Value?

Anixa Biosciences ANIX -2.47% 27 ROE % Adjusted to Book Value is -9.69% as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Anixa Biosciences's ROE % for the quarter that ended in Apr. 2026 was -68.11%. Anixa Biosciences's PB Ratio for the quarter that ended in Apr. 2026 was 7.03. Anixa Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Apr. 2026 was -9.69%.

Anixa Biosciences ROE % Adjusted to Book Value Related Terms

Anixa Biosciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences ROE % Adjusted to Book Value Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.47 -7.07 -9.08 -10.04 -6.91

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.77 -9.14 -7.54 -10.07 -9.69

ANIX vs PYPD, LONA, SGMO: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Anixa Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anixa Biosciences ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's ROE % Adjusted to Book Value falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences ROE % Adjusted to Book Value Calculation

Anixa Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Oct. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-62.16% / 9.00
=-6.91%

Anixa Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Apr. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-68.11% / 7.03
=-9.69%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -9.69% mean?
Anixa Biosciences (ANIX) has a ROE % Adjusted to Book Value of -9.69% as of Apr. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Anixa Biosciences and its competitors.
Is Anixa Biosciences' ROE % Adjusted to Book Value too high?
Anixa Biosciences' current ROE % Adjusted to Book Value is -9.69%. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' ROE % Adjusted to Book Value compare to PYPD and LONA?
Anixa Biosciences' ROE % Adjusted to Book Value of -9.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current ROE % Adjusted to Book Value is -9.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current ROE % Adjusted to Book Value of -9.69%. The current ROE % Adjusted to Book Value is -9.69%. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current ROE % Adjusted to Book Value is -9.69% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.57
Price